|
Once a Sneak, a company becomes a candidate for a full recommenda-tion. My decision concerning which to recommend is based on what we find in continuing investigation. I may cover a Sneak I did a year ago, or one from the last issue; do not attach significance to timing. While Sneaks are preliminary recommenda-tions, do not use them for investment decisions unless you decide on the basis of facts you uncover in your own investiga-tion. Keep in mind that the codes listed after each Sneak are preliminary, reflecting my first impression. They are subject to change based on further investigation. A.L.I. Technologies, Inc. (TSE/ALT) is a medical information management technology company that develops & markets filmless diagnostic image & clinical report management systems for use in imaging departments within hospitals & clinics. Its diagnostic image management solutions are available in several levels, all of which improve the delivery of medical imaging services. Its top-of-the-line ALI UltraPACSR electronically captures the images from an entire imaging facility which may be spread over a campus, city, region, or boundless wide area network. These images are archived as long-term patient records on optical media, allowing the diagnostician to compare past images with present images in making a critical evaluation. ALT has the world's largest installed base of filmless image management systems. As of the end of 1998, it had 208 systems installed in such facilities as: Beth Isra-el/Deaconess - Boston; Duke University Medical Center - Durham; Johns Hopkins - Baltimore; Mayo Clinics - Jacksonville, Rochester, & Scottsdale; & the National Naval Medical Center - Bethesda. In addition, there are more than 50 installations in foreign countries. The company sees significant growth opportunities in the area of ultrasound image management solutions & is focusing on that market for the near term. Between 1993 & 1998, sales increased by a factor of 28 (averaging almost 100 percent growth per year) & achieved significant net income improvements in each of the last three years. Call IR J. Caren Holtby @ 800-661-5885, fax 800-261-5432, or write 95 - 10551 Shellbridge Way, Richmond, BC, Canada V6X 2W9. www.alitech-.com [R-7; M-7; L-8] Amerigon Incorporated (NASDAQ/ARGNA) develops, manufactures, & markets proprietary high technology automotive components & systems for sale to automobile & other OEMs. The automobile business is highly competitive. Manufacturers must win customers by offering new features which differentiate them from their competitors while adding additional profit margin. To assist in achieving these goals, ARGNA focuses on two specific technologies; climate controlled seats, & radar systems for maneuverabili-ty & safety. The Climate Control Seat (CCS): Although seat-warming systems have been available on some cars for decades, the older models offer only warming through electric resistance wires embedded in the seat cover. CCS not only warms, but also cools, & dries vehicle seats instantaneously at the touch of a finger by means of an air-flow generating solid-state electronic heat pump. There is no waiting for the engine to warm up or the air conditioner to kick in. Each passenger can control his or her seat as they wish. Extreme cold, or hot sticky weather are no longer a problem. CCS is efficient, quiet, environmen-tally friendly (no moving parts or refrigerant), & less costly to produce. ARGNA shipped production seats to Florida-based Mark III Industries, the leading manufacturer of conversion vans, minivans & trucks. These seats were featured earlier this year at the National Automobile Dealers Association (NADA) convention in New Orleans. The Climate Control Seat (CCS): Although seat-warming systems have been available on some cars for decades, the older models offer only warming through electric resistance wires embedded in the seat cover. CCS not only warms, but also cools, & dries vehicle seats instantaneously at the touch of a finger by means of an air-flow generating solid-state electronic heat pump. There is no waiting for the engine to warm up or the air conditioner to kick in. Each passenger can control his or her seat as they wish. Extreme cold, or hot sticky weather are no longer a problem. CCS is efficient, quiet, environmen-tally friendly (no moving parts or refrigerant), & less costly to produce. ARGNA shipped production seats to Florida-based Mark III Industries, the leading manufacturer of conversion vans, minivans & trucks. These seats were featured earlier this year at the National Automobile Dealers Association (NADA) convention in New Orleans.
|
HemaCare Corporation (NASDAQ/HEMA) is a leading provider of blood products & services to healthcare organizations primarily in southern CA. HEMA, founded in 1978, was the first publicly traded company in the $2 billion U.S. blood industry to be licensed by the FDA & accredited by the American Association of Blood Banks. HEMA's Blood Management Program (BMP) is an arrangement in which the healthcare organization outsources its blood procurement & donor center management to HEMA. Donors are carefully screened in compliance with industry & regulatory standards. Unlike Red Cross blood drives, HEMA's donors are reimbursed for their time & commitment, thus assuring a safe, continuing blood supply. Since its inception, the company has also performed more than 35,000 therapeutic apheresis procedures; a technique for removing harmful components from a patient's blood used in the treatment of autoimmune diseases & other disorders. These services are provided on request by the healthcare organization which is billed directly. HEMA uses self-contained, state-of-the-art mobile units operated at the patient's bedside or in a hospital outpatient setting. This two to four hour procedure may be required from four to 20 times over a period of time ranging from a few days to several months. It is used in patients suffering from a number of diseases such as multiple myeloma, HIV-polyneuropathy, leukemia, systemic lupus erythematosus, lupus nephritis, & scleroderma. Call Admin. Services Dir. Joann R. Stover @ 818-986-3883, fax 818-986-1417, or write 4954 Van Nuys Blvd., Sherman Oaks, CA 91403. [R-7; M-7; L-8] Infocall Communications Corp. (OTC Bulletin Board/INFE) is positioning itself to become an important force in the employment staffing industry (market size for 1998 about $103.8 billion). It specializes in the rapid growth areas of information technology (IT) staffing & consulting & the employee leasing or Professional Employer Organization (PEO) industry sectors. It also provides Internet-based recruiting services using its proprietary software, "Resumes/ASAP." The Wall Street Journal says the PEO sector is estimated at 26% or $27 billion, & expected to expand to $1.4 trillion. The IT staffing sector is estimated at 18% of that industry or $18.5 billion & is growing at an average of 27% per year. The National Capital Companies says "Infocall is positioned to grow from about $20 million in revenues in FY ending 2/28/99 to a projected $100 million in FY 2000. Net income for 2000 is projected to come in at $4.1 million or $0.33 per share on a fully diluted basis. We are expecting Infocall to reach $200 million in revenues by FY ending 2/28/2001, with net income of $12.9 million or a fully diluted $0.76 per share." Call 949-261-2101, fax 949-261-2492, or write National Capital @ 18952 MacArthur Blvd., Suite 315, Irvine, CA 92612. [R-7; M-7; L-8] KOS Pharmaceuticals, Inc. (NASDAQ/KOSP) is a fully integrated specialty pharmaceutical company that develops proprietary prescription products, primarily for treatment of cardiovascular & respiratory diseases. Its lead product, NiaspinR, is the only extended-release, Once-A-NightTM niacin tablet formulation FDA approved for the treatment of mixed lipid disorders (a primary risk factor for coronary heart disease). This product effectively reduces the "bad" cholesterol (LDL) & increases the "good" cholesterol (HDL). Niaspin(R), unlike over-the-counter niacin dietary supplements, will not cause liver problems & is much safer. The market for such products is estimated to be $4 billion, covering over 17 million patients in the U.S. KOS is well positioned to be a significant player in this field. Niaspin(R) is marketed through KOS's 200-member sales force calling on physicians who prescribe cholesterol-altering drugs -- a group of practitioners including cardiologists & internists, along with general & family physicians. Since the product's launch, about 8,700 doctors have written 60,552 Niaspin prescriptions. Plans are underway to market Niaspin in Europe. KOS has six additional products in its development pipeline: three
once-daily tablet formulations for the treatment of cardiovascular
disease & three aerosolized inhalation formulations for the treatment
of respiratory diseases. Its strategy focuses on reformulating existing
prescription pharmaceutical products to improve safety or patient
compliance. ...continued on next page, click here |
|
|
|
Disclaimer: The public companies featured in the Research Reports or Corporate Profiles listed in the "Special Situation" section on the Home Page of www.WallStreetCorner.com (WSC) are our regular clients. Each such client, as of 12/1/2009, pays a modest cash fee for our three-month trial period, & on occasion may provide us with a negotiated number of Form 144 restricted shares as an incentive for our service. We may accept free-trading shares, but we usually hold such shares for the long pull – we do not engage in trading. Such fees are disclosed as part of the Research Report or Corporate Profile prepared & posted on the particular client company involved. The basic coverage provided to such clients primarily includes the preparation of their Research Report or Corporate Profile, posting it here at WallStreetCorner.com, & the distribution of email alerts to our international database of investors and financial professionals when their Report or Profile is initially posted, & each time their Report or Profile is subsequently updated. We expect our clients to work with us in a team effort by calling us each time they have achieved a significant milestone. We then update their Report or Profile & issue an additional email alert to our totally opt-in email database (as of December 2009, members of that database are from over 96 countries). The email distributions we make are a key element of our service -- those, as well as the updated Research Report or Corporate Profile are what together are designed to achieve a gradual buildup of new shareholders who generally hold for the long term. If you are an officer at a public company & want the exposure afforded at WallStreetCorner.com, email Larry Oakley at up415@aol.com or call him at 843-645-2729. Information displayed by WallStreetCorner in its Research Reports or Corporate Profiles, & in its editorial or other columns, does not constitute an offer to buy, sell, or trade a security of any kind, including stock. Larry Oakley, &/or WallStreetCorner.com, Inc., does not recommend that any person, institution, or other entity make any decisions or form any opinions, etc. based on the information on this site. All visitors to this site are urged to do two things before investing in any stock: (1) Call the company and ask questions -- if there is anything you do not like regarding such a call, pass -- our goal is to bring you a selection of what we feel are growth situations with good long-term appreciation potential, but you must accept the responsibility of making your own decisions regarding which situations to invest in -- do not give up that responsibility; and (2) Examine the company’s latest financial information usually available on the company’s web site, and consult a qualified financial professional before taking any actions in regards to buying, selling, or trading securities (stocks or other forms of equity). Companies covered in Conservative Speculator, a newsletter accessed from WallStreetCorner, or in any of Larry Oakley's other editorial venues ("Opinion," "Stock Pick," “Comment,” and "Bold Ventures" columns, or in any other editorial venue to which Larry contributes) do not pay for such editorial coverage; the companies Larry covers editorially have never, do not now, and never will be charged for editorial coverage. The only paid portions of WallStreetCorner.com are the Research Reports & Corporate Profiles plus the email distributions that are a part of the client’s package. On occasion, Larry Oakley shares his opinion regarding a private company or its product or service. Bear in mind that nothing at that special section is an investment possibility. To see that section, click where on the home page it says: “Click here to access our Special Emerging Growth Situations.” See the introductory portion of that special section for additional information regarding the material covered there. The service provided to our readers here at WallStreetCorner is on an "as is" basis only. Neither we, nor any licensor or third party provider of any component of the service or of any information delivered as part of the service, makes, & each expressly disclaims, any representation or warranty of any kind, whether expressed, implied, or arising out of course of dealing or usage, including without limitation any warranty of fitness for a particular purpose, noninfringement, noninterference with data, availability, accuracy, or that the service is error-free or secure. The service occasionally contains information provided by one or more third party persons or firms or other third party data providers. We do not control & are not responsible for the information provided by any such third party provider. We specifically are not responsible for any damages caused by non-delivery, delayed delivery, or the misdirected delivery of an email Alert, update, editorial, Special Situation coverage, or other information, inaccurate or incomplete information in an Alert, update, editorial, Special Situation coverage, or other information, or your reliance on or use of any Alert, update, editorial, Special Situation coverage, or other information. We assume no responsibility for the timeliness, deletion, mis-delivery, or accuracy of any editorials, Research Reports, Corporate Profiles, Special Situation coverage, or any & all other content at this site. In no event may we, or any licensor or third party provider of any component of our service or of any information delivered as part of the service, be liable for any consequential, indirect, special, exemplary, punitive, or similar damages arising from or related to the service, even if advised of the possibility of such. |
|
|
WallStreetCorner.com |
